Van ECK Associates Corp Purchases 44,338 Shares of Edwards Lifesciences Co. (NYSE:EW)

Van ECK Associates Corp grew its position in Edwards Lifesciences Co. (NYSE:EW) by 35.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 171,102 shares of the medical research company’s stock after buying an additional 44,338 shares during the period. Van ECK Associates Corp’s holdings in Edwards Lifesciences were worth $12,666,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in EW. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. Jennison Associates LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $555,939,000. Assenagon Asset Management S.A. raised its stake in shares of Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after buying an additional 3,506,886 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after buying an additional 2,606,950 shares during the period. Finally, Seilern Investment Management Ltd bought a new position in Edwards Lifesciences in the fourth quarter valued at approximately $109,490,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Piper Sandler upped their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday. Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Robert W. Baird reduced their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday. Finally, Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Up 0.3 %

NYSE:EW opened at $76.23 on Friday. The company has a market cap of $44.96 billion, a P/E ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The business has a 50 day moving average price of $72.67 and a two-hundred day moving average price of $69.50. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock worth $2,002,829 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.